Novel adjuvants and vaccine delivery systems
Identifieur interne : 000655 ( Istex/Corpus ); précédent : 000654; suivant : 000656Novel adjuvants and vaccine delivery systems
Auteurs : Bror Morein ; María Villacrés-Eriksson ; Anders Sjölander ; Karin Lövgren BengtssonSource :
- Veterinary Immunology and Immunopathology [ 0165-2427 ] ; 1996.
English descriptors
- Teeft :
- Adjuvant, Adjuvant activity, Allergy appl, Aluminium hydroxide, Antibody formation, Benner, Boca raton, Bone marrow, Cell culture work, Cell response, Cell responses, Complete adjuvant, Cytokine, Delivery systems, Dendritic cells, Depot effect, Dextran sulphate, Digestive tract, High doses, Hydroxide, Immune, Immune response, Immune responses, Immunization, Immunol, Immunology, Important task, Influenza, Influenza virus, Influenza virus envelope, Influenza virus iscoms, Iscom, Iscom matrix, Iscoms, Liposome, Long period, Lovgren bengtsson, Lymph, Lymph nodes, Lymphatic system, Macrophage, Memory cells, Microspheres, Morein, Mucosal, Node, Novel delivery systems, Oral vaccines, Particulate form, Proliferative response, Respiratory tract, Spherical particles, Spleen, Subunit, Unpublished data, Vaccine.
Abstract
Abstract: Conventionally the efficiency of an adjuvant is measured by the capacity to induce enhanced antibody serum titres and cell mediated immunity (CMI) to a given antigen. Nowadays the capacity of an adjuvant is also measured by the quality as well as the magnitude of the induced immune response, guided by the protective immune response required. Quality includes isotype and IgG subclass responses, T-helper cell responses characterized by the cytokine profile and cytotoxic T cells (CTL). In the early phase of immunization some adjuvants influence the antigen administration and uptake by a so- called depot effect exemplified by aluminium hydroxide gel and oil adjuvants, which possibly is not as desired as alledged. A modern depot is exerted by slow release formulations continuously releasing the antigen over a period of time or by pulses at intervals aiming at ‘single injection’ vaccine. Great efforts are made to formulate efficient delivery formulations targeting the antigens from the site of administration, to draining lymph nodes or distant lymphatic tissue or to mucosal surfaces by parenteral or mucosal administrations. Nowadays, non-replicating carriers besides replicating vaccines are formulated to induce mucosal immune responses encompassing secretory IgA and CMI. Efforts to evoke immune responses on mucosal membranes distant from the site of administration have resulted mostly in little success. For a long time it was considered that CTL under the restriction of MHC Class I only could be evoked by replicating viruses or intracellular parasites. However, novel adjuvant delivery systems readily induce CTL by delivering the antigen to the APC resulting in intracellular transport to the cytosol for the MHC Class I presentation system, as well as to the endosomal pathway for the MHC Class II presentation.
Url:
DOI: 10.1016/S0165-2427(96)05697-8
Links to Exploration step
ISTEX:E36E830A8DEA0E8E1025E05505689770D30009C4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Novel adjuvants and vaccine delivery systems</title><author><name sortKey="Morein, Bror" sort="Morein, Bror" uniqKey="Morein B" first="Bror" last="Morein">Bror Morein</name><affiliation><mods:affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Villacres Eriksson, Maria" sort="Villacres Eriksson, Maria" uniqKey="Villacres Eriksson M" first="María" last="Villacrés-Eriksson">María Villacrés-Eriksson</name><affiliation><mods:affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Sjolander, Anders" sort="Sjolander, Anders" uniqKey="Sjolander A" first="Anders" last="Sjölander">Anders Sjölander</name><affiliation><mods:affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Lovgren Bengtsson, Karin" sort="Lovgren Bengtsson, Karin" uniqKey="Lovgren Bengtsson K" first="Karin" last="Lövgren Bengtsson">Karin Lövgren Bengtsson</name><affiliation><mods:affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E36E830A8DEA0E8E1025E05505689770D30009C4</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1016/S0165-2427(96)05697-8</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-D1SBLW3D-2/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000655</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000655</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Novel adjuvants and vaccine delivery systems</title><author><name sortKey="Morein, Bror" sort="Morein, Bror" uniqKey="Morein B" first="Bror" last="Morein">Bror Morein</name><affiliation><mods:affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Villacres Eriksson, Maria" sort="Villacres Eriksson, Maria" uniqKey="Villacres Eriksson M" first="María" last="Villacrés-Eriksson">María Villacrés-Eriksson</name><affiliation><mods:affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Sjolander, Anders" sort="Sjolander, Anders" uniqKey="Sjolander A" first="Anders" last="Sjölander">Anders Sjölander</name><affiliation><mods:affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Lovgren Bengtsson, Karin" sort="Lovgren Bengtsson, Karin" uniqKey="Lovgren Bengtsson K" first="Karin" last="Lövgren Bengtsson">Karin Lövgren Bengtsson</name><affiliation><mods:affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Veterinary Immunology and Immunopathology</title><title level="j" type="abbrev">VETIMM</title><idno type="ISSN">0165-2427</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1996">1996</date><biblScope unit="volume">54</biblScope><biblScope unit="issue">1–4</biblScope><biblScope unit="page" from="373">373</biblScope><biblScope unit="page" to="384">384</biblScope></imprint><idno type="ISSN">0165-2427</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0165-2427</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adjuvant</term><term>Adjuvant activity</term><term>Allergy appl</term><term>Aluminium hydroxide</term><term>Antibody formation</term><term>Benner</term><term>Boca raton</term><term>Bone marrow</term><term>Cell culture work</term><term>Cell response</term><term>Cell responses</term><term>Complete adjuvant</term><term>Cytokine</term><term>Delivery systems</term><term>Dendritic cells</term><term>Depot effect</term><term>Dextran sulphate</term><term>Digestive tract</term><term>High doses</term><term>Hydroxide</term><term>Immune</term><term>Immune response</term><term>Immune responses</term><term>Immunization</term><term>Immunol</term><term>Immunology</term><term>Important task</term><term>Influenza</term><term>Influenza virus</term><term>Influenza virus envelope</term><term>Influenza virus iscoms</term><term>Iscom</term><term>Iscom matrix</term><term>Iscoms</term><term>Liposome</term><term>Long period</term><term>Lovgren bengtsson</term><term>Lymph</term><term>Lymph nodes</term><term>Lymphatic system</term><term>Macrophage</term><term>Memory cells</term><term>Microspheres</term><term>Morein</term><term>Mucosal</term><term>Node</term><term>Novel delivery systems</term><term>Oral vaccines</term><term>Particulate form</term><term>Proliferative response</term><term>Respiratory tract</term><term>Spherical particles</term><term>Spleen</term><term>Subunit</term><term>Unpublished data</term><term>Vaccine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Conventionally the efficiency of an adjuvant is measured by the capacity to induce enhanced antibody serum titres and cell mediated immunity (CMI) to a given antigen. Nowadays the capacity of an adjuvant is also measured by the quality as well as the magnitude of the induced immune response, guided by the protective immune response required. Quality includes isotype and IgG subclass responses, T-helper cell responses characterized by the cytokine profile and cytotoxic T cells (CTL). In the early phase of immunization some adjuvants influence the antigen administration and uptake by a so- called depot effect exemplified by aluminium hydroxide gel and oil adjuvants, which possibly is not as desired as alledged. A modern depot is exerted by slow release formulations continuously releasing the antigen over a period of time or by pulses at intervals aiming at ‘single injection’ vaccine. Great efforts are made to formulate efficient delivery formulations targeting the antigens from the site of administration, to draining lymph nodes or distant lymphatic tissue or to mucosal surfaces by parenteral or mucosal administrations. Nowadays, non-replicating carriers besides replicating vaccines are formulated to induce mucosal immune responses encompassing secretory IgA and CMI. Efforts to evoke immune responses on mucosal membranes distant from the site of administration have resulted mostly in little success. For a long time it was considered that CTL under the restriction of MHC Class I only could be evoked by replicating viruses or intracellular parasites. However, novel adjuvant delivery systems readily induce CTL by delivering the antigen to the APC resulting in intracellular transport to the cytosol for the MHC Class I presentation system, as well as to the endosomal pathway for the MHC Class II presentation.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>adjuvant</json:string><json:string>morein</json:string><json:string>immune</json:string><json:string>iscoms</json:string><json:string>immunol</json:string><json:string>iscom</json:string><json:string>vaccine</json:string><json:string>immune response</json:string><json:string>macrophage</json:string><json:string>node</json:string><json:string>subunit</json:string><json:string>immunology</json:string><json:string>microspheres</json:string><json:string>lymph nodes</json:string><json:string>liposome</json:string><json:string>mucosal</json:string><json:string>cytokine</json:string><json:string>benner</json:string><json:string>hydroxide</json:string><json:string>immunization</json:string><json:string>aluminium hydroxide</json:string><json:string>adjuvant activity</json:string><json:string>cell response</json:string><json:string>cell responses</json:string><json:string>particulate form</json:string><json:string>immune responses</json:string><json:string>influenza virus</json:string><json:string>influenza</json:string><json:string>lymphatic system</json:string><json:string>influenza virus iscoms</json:string><json:string>oral vaccines</json:string><json:string>lymph</json:string><json:string>spleen</json:string><json:string>spherical particles</json:string><json:string>bone marrow</json:string><json:string>complete adjuvant</json:string><json:string>dendritic cells</json:string><json:string>antibody formation</json:string><json:string>influenza virus envelope</json:string><json:string>dextran sulphate</json:string><json:string>long period</json:string><json:string>important task</json:string><json:string>delivery systems</json:string><json:string>high doses</json:string><json:string>unpublished data</json:string><json:string>memory cells</json:string><json:string>digestive tract</json:string><json:string>cell culture work</json:string><json:string>proliferative response</json:string><json:string>iscom matrix</json:string><json:string>respiratory tract</json:string><json:string>depot effect</json:string><json:string>allergy appl</json:string><json:string>lovgren bengtsson</json:string><json:string>novel delivery systems</json:string><json:string>boca raton</json:string></teeft></keywords><author><json:item><name>Bror Morein</name><affiliations><json:string>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</json:string></affiliations></json:item><json:item><name>María Villacrés-Eriksson</name><affiliations><json:string>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</json:string></affiliations></json:item><json:item><name>Anders Sjölander</name><affiliations><json:string>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</json:string></affiliations></json:item><json:item><name>Karin Lövgren Bengtsson</name><affiliations><json:string>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Vaccines</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Adjuvants</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Antigen delivery systems</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Immune modulation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Cytokine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Cell mediated immunity</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Antibody mediated immunity</value></json:item></subject><arkIstex>ark:/67375/6H6-D1SBLW3D-2</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Abstract: Conventionally the efficiency of an adjuvant is measured by the capacity to induce enhanced antibody serum titres and cell mediated immunity (CMI) to a given antigen. Nowadays the capacity of an adjuvant is also measured by the quality as well as the magnitude of the induced immune response, guided by the protective immune response required. Quality includes isotype and IgG subclass responses, T-helper cell responses characterized by the cytokine profile and cytotoxic T cells (CTL). In the early phase of immunization some adjuvants influence the antigen administration and uptake by a so- called depot effect exemplified by aluminium hydroxide gel and oil adjuvants, which possibly is not as desired as alledged. A modern depot is exerted by slow release formulations continuously releasing the antigen over a period of time or by pulses at intervals aiming at ‘single injection’ vaccine. Great efforts are made to formulate efficient delivery formulations targeting the antigens from the site of administration, to draining lymph nodes or distant lymphatic tissue or to mucosal surfaces by parenteral or mucosal administrations. Nowadays, non-replicating carriers besides replicating vaccines are formulated to induce mucosal immune responses encompassing secretory IgA and CMI. Efforts to evoke immune responses on mucosal membranes distant from the site of administration have resulted mostly in little success. For a long time it was considered that CTL under the restriction of MHC Class I only could be evoked by replicating viruses or intracellular parasites. However, novel adjuvant delivery systems readily induce CTL by delivering the antigen to the APC resulting in intracellular transport to the cytosol for the MHC Class I presentation system, as well as to the endosomal pathway for the MHC Class II presentation.</abstract><qualityIndicators><score>9.188</score><pdfWordCount>4188</pdfWordCount><pdfCharCount>26622</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>12</pdfPageCount><pdfPageSize>468 x 684 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>280</abstractWordCount><abstractCharCount>1843</abstractCharCount><keywordCount>7</keywordCount></qualityIndicators><title>Novel adjuvants and vaccine delivery systems</title><pmid><json:string>8988882</json:string></pmid><pii><json:string>S0165-2427(96)05697-8</json:string></pii><genre><json:string>research-article</json:string></genre><host><title>Veterinary Immunology and Immunopathology</title><language><json:string>unknown</json:string></language><publicationDate>1996</publicationDate><issn><json:string>0165-2427</json:string></issn><pii><json:string>S0165-2427(00)X0022-0</json:string></pii><volume>54</volume><issue>1–4</issue><pages><first>373</first><last>384</last></pages><genre><json:string>journal</json:string></genre><conference><json:item><name>Proceedings of the International Veterinary Immunology Symposium, Davis, California IVIS 199507</name></json:item></conference><editor><json:item><name>Patricia E. Shewen</name></json:item><json:item><name>Joan K. Lunney</name></json:item><json:item><name>Laurel J. Gershwin</name></json:item></editor></host><namedEntities><unitex><date><json:string>199507</json:string><json:string>1970s</json:string><json:string>1996</json:string></date><geogName></geogName><orgName><json:string>National Veterinary Institute, Department of Virology, Biomedical Centre</json:string><json:string>Sweden Abstract Conventionally</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>H. Nl</json:string><json:string>Excellent</json:string><json:string>Anders Sjblander</json:string><json:string>Laurel J. Gershwin</json:string><json:string>Joan K. Lunney</json:string><json:string>Maria Villacrks-Eriksson</json:string></persName><placeName></placeName><ref_url></ref_url><ref_bibl><json:string>Dickinson and Clements, 1995</json:string><json:string>Fontana et al.</json:string><json:string>Bornford, 1984</json:string><json:string>Babuik et al. (1994)</json:string><json:string>Adams et al., 1987</json:string><json:string>Benner et al., 1981 b</json:string><json:string>Liivgren et al.. 19901</json:string><json:string>Morein and Simons, 1985</json:string><json:string>Deuce et al., 1995</json:string><json:string>Cox and Coulter, 1992</json:string><json:string>McMenamin et al.. 1991</json:string><json:string>Lazarova et al.. 1996</json:string><json:string>Santos et al.. 19901</json:string><json:string>Benner et al., 1981b</json:string><json:string>Artursson et al., 1986</json:string><json:string>Benner et al.</json:string><json:string>Sjolander et al.</json:string><json:string>Harding et al., 1991</json:string><json:string>Deres et al., 1989</json:string><json:string>Eldridge et al. (1990)</json:string><json:string>Watson et al. (1992)</json:string><json:string>Morein et al., 1995</json:string><json:string>Benner et al., 1981a</json:string><json:string>Morein et al., 1978</json:string><json:string>Jenkins et al., 19901</json:string><json:string>De Haan et al.. 1995</json:string><json:string>Wajdy and Lycke, 1993</json:string><json:string>Lewis, 1990</json:string><json:string>Thies, 1989</json:string><json:string>Hbglund et al., 1989</json:string><json:string>Lazarova et al. (1996)</json:string><json:string>Eriksson et al., 1995</json:string><json:string>Labbe et al., 1991</json:string><json:string>Eldridge et al., 19901</json:string><json:string>Carayanniotis and Barber, 1987</json:string><json:string>Takahashi et al.. 1990</json:string><json:string>Trinchieri, 1993</json:string><json:string>B. Morein et al.</json:string><json:string>Gall, 1966</json:string><json:string>Mowat and Malay, 1994</json:string><json:string>O’Hagan, 1994</json:string><json:string>Adams et al.. 1987</json:string><json:string>Eldridge et al.. 1991</json:string><json:string>Claassen et al.. 1992</json:string><json:string>Weiner et al.. 19941</json:string><json:string>Almeida et al.</json:string><json:string>Staats et al., 1994</json:string><json:string>Davis and Illum, 1989</json:string><json:string>Jones et al.</json:string><json:string>Wilschut et al.. 1994</json:string><json:string>Takahashi et al., 1990</json:string><json:string>SjBlander et al., 1996a</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-D1SBLW3D-2</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - veterinary sciences</json:string><json:string>2 - immunology</json:string></wos><scienceMetrix><json:string>1 - applied sciences</json:string><json:string>2 - agriculture, fisheries & forestry</json:string><json:string>3 - veterinary sciences</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Veterinary</json:string><json:string>3 - General Veterinary</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Immunology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>1996</publicationDate><copyrightDate>1996</copyrightDate><doi><json:string>10.1016/S0165-2427(96)05697-8</json:string></doi><id>E36E830A8DEA0E8E1025E05505689770D30009C4</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-D1SBLW3D-2/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-D1SBLW3D-2/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-D1SBLW3D-2/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">Novel adjuvants and vaccine delivery systems</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>1996</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Novel adjuvants and vaccine delivery systems</title><author xml:id="author-0000"><persName><forename type="first">Bror</forename><surname>Morein</surname></persName><note type="correspondence"><p>Corresponding author.</p></note><affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</affiliation></author><author xml:id="author-0001"><persName><forename type="first">María</forename><surname>Villacrés-Eriksson</surname></persName><affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Anders</forename><surname>Sjölander</surname></persName><affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Karin</forename><surname>Lövgren Bengtsson</surname></persName><affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</affiliation></author><idno type="istex">E36E830A8DEA0E8E1025E05505689770D30009C4</idno><idno type="ark">ark:/67375/6H6-D1SBLW3D-2</idno><idno type="DOI">10.1016/S0165-2427(96)05697-8</idno><idno type="PII">S0165-2427(96)05697-8</idno></analytic><monogr><title level="j">Veterinary Immunology and Immunopathology</title><title level="j" type="abbrev">VETIMM</title><idno type="pISSN">0165-2427</idno><idno type="PII">S0165-2427(00)X0022-0</idno><meeting><addName>Proceedings of the International Veterinary Immunology Symposium, Davis, California</addName><addName>IVIS</addName><date>199507</date></meeting><editor xml:id="book-author-0000"><persName>Patricia E. Shewen</persName></editor><editor xml:id="book-author-0001"><persName>Joan K. Lunney</persName></editor><editor xml:id="book-author-0002"><persName>Laurel J. Gershwin</persName></editor><imprint><publisher>ELSEVIER</publisher><date type="published" when="1996"></date><biblScope unit="volume">54</biblScope><biblScope unit="issue">1–4</biblScope><biblScope unit="page" from="373">373</biblScope><biblScope unit="page" to="384">384</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1996</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: Conventionally the efficiency of an adjuvant is measured by the capacity to induce enhanced antibody serum titres and cell mediated immunity (CMI) to a given antigen. Nowadays the capacity of an adjuvant is also measured by the quality as well as the magnitude of the induced immune response, guided by the protective immune response required. Quality includes isotype and IgG subclass responses, T-helper cell responses characterized by the cytokine profile and cytotoxic T cells (CTL). In the early phase of immunization some adjuvants influence the antigen administration and uptake by a so- called depot effect exemplified by aluminium hydroxide gel and oil adjuvants, which possibly is not as desired as alledged. A modern depot is exerted by slow release formulations continuously releasing the antigen over a period of time or by pulses at intervals aiming at ‘single injection’ vaccine. Great efforts are made to formulate efficient delivery formulations targeting the antigens from the site of administration, to draining lymph nodes or distant lymphatic tissue or to mucosal surfaces by parenteral or mucosal administrations. Nowadays, non-replicating carriers besides replicating vaccines are formulated to induce mucosal immune responses encompassing secretory IgA and CMI. Efforts to evoke immune responses on mucosal membranes distant from the site of administration have resulted mostly in little success. For a long time it was considered that CTL under the restriction of MHC Class I only could be evoked by replicating viruses or intracellular parasites. However, novel adjuvant delivery systems readily induce CTL by delivering the antigen to the APC resulting in intracellular transport to the cytosol for the MHC Class I presentation system, as well as to the endosomal pathway for the MHC Class II presentation.</p></abstract><textClass><keywords scheme="keyword"><list><head>article-category</head><item><term>Vaccines</term></item></list></keywords></textClass><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>Adjuvants</term></item><item><term>Antigen delivery systems</term></item><item><term>Immune modulation</term></item><item><term>Cytokine</term></item><item><term>Cell mediated immunity</term></item><item><term>Antibody mediated immunity</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1996">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-D1SBLW3D-2/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>VETIMM</jid><aid>96056978</aid><ce:pii>S0165-2427(96)05697-8</ce:pii><ce:doi>10.1016/S0165-2427(96)05697-8</ce:doi><ce:copyright type="unknown" year="1996"></ce:copyright><ce:doctopics><ce:doctopic><ce:text>Vaccines</ce:text></ce:doctopic></ce:doctopics></item-info><head><ce:title>Novel adjuvants and vaccine delivery systems</ce:title><ce:author-group><ce:author><ce:given-name>Bror</ce:given-name><ce:surname>Morein</ce:surname><ce:cross-ref refid="COR1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>María</ce:given-name><ce:surname>Villacrés-Eriksson</ce:surname></ce:author><ce:author><ce:given-name>Anders</ce:given-name><ce:surname>Sjölander</ce:surname></ce:author><ce:author><ce:given-name>Karin</ce:given-name><ce:surname>Lövgren Bengtsson</ce:surname></ce:author><ce:affiliation><ce:textfn>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Corresponding author.</ce:text></ce:correspondence></ce:author-group><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>Conventionally the efficiency of an adjuvant is measured by the capacity to induce enhanced antibody serum titres and cell mediated immunity (CMI) to a given antigen. Nowadays the capacity of an adjuvant is also measured by the quality as well as the magnitude of the induced immune response, guided by the protective immune response required. Quality includes isotype and IgG subclass responses, T-helper cell responses characterized by the cytokine profile and cytotoxic T cells (CTL). In the early phase of immunization some adjuvants influence the antigen administration and uptake by a so- called depot effect exemplified by aluminium hydroxide gel and oil adjuvants, which possibly is not as desired as alledged. A modern depot is exerted by slow release formulations continuously releasing the antigen over a period of time or by pulses at intervals aiming at ‘single injection’ vaccine. Great efforts are made to formulate efficient delivery formulations targeting the antigens from the site of administration, to draining lymph nodes or distant lymphatic tissue or to mucosal surfaces by parenteral or mucosal administrations. Nowadays, non-replicating carriers besides replicating vaccines are formulated to induce mucosal immune responses encompassing secretory IgA and CMI. Efforts to evoke immune responses on mucosal membranes distant from the site of administration have resulted mostly in little success. For a long time it was considered that CTL under the restriction of MHC Class I only could be evoked by replicating viruses or intracellular parasites. However, novel adjuvant delivery systems readily induce CTL by delivering the antigen to the APC resulting in intracellular transport to the cytosol for the MHC Class I presentation system, as well as to the endosomal pathway for the MHC Class II presentation.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Adjuvants</ce:text></ce:keyword><ce:keyword><ce:text>Antigen delivery systems</ce:text></ce:keyword><ce:keyword><ce:text>Immune modulation</ce:text></ce:keyword><ce:keyword><ce:text>Cytokine</ce:text></ce:keyword><ce:keyword><ce:text>Cell mediated immunity</ce:text></ce:keyword><ce:keyword><ce:text>Antibody mediated immunity</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Novel adjuvants and vaccine delivery systems</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Novel adjuvants and vaccine delivery systems</title></titleInfo><name type="personal"><namePart type="given">Bror</namePart><namePart type="family">Morein</namePart><affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</affiliation><description>Corresponding author.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">María</namePart><namePart type="family">Villacrés-Eriksson</namePart><affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anders</namePart><namePart type="family">Sjölander</namePart><affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Karin</namePart><namePart type="family">Lövgren Bengtsson</namePart><affiliation>Swedish University of Agricultural Sciences and The National Veterinary Institute, Department of Virology, Biomedical Centre, Box 585, S-751 23, Uppsala, Sweden</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1996</dateIssued><copyrightDate encoding="w3cdtf">1996</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: Conventionally the efficiency of an adjuvant is measured by the capacity to induce enhanced antibody serum titres and cell mediated immunity (CMI) to a given antigen. Nowadays the capacity of an adjuvant is also measured by the quality as well as the magnitude of the induced immune response, guided by the protective immune response required. Quality includes isotype and IgG subclass responses, T-helper cell responses characterized by the cytokine profile and cytotoxic T cells (CTL). In the early phase of immunization some adjuvants influence the antigen administration and uptake by a so- called depot effect exemplified by aluminium hydroxide gel and oil adjuvants, which possibly is not as desired as alledged. A modern depot is exerted by slow release formulations continuously releasing the antigen over a period of time or by pulses at intervals aiming at ‘single injection’ vaccine. Great efforts are made to formulate efficient delivery formulations targeting the antigens from the site of administration, to draining lymph nodes or distant lymphatic tissue or to mucosal surfaces by parenteral or mucosal administrations. Nowadays, non-replicating carriers besides replicating vaccines are formulated to induce mucosal immune responses encompassing secretory IgA and CMI. Efforts to evoke immune responses on mucosal membranes distant from the site of administration have resulted mostly in little success. For a long time it was considered that CTL under the restriction of MHC Class I only could be evoked by replicating viruses or intracellular parasites. However, novel adjuvant delivery systems readily induce CTL by delivering the antigen to the APC resulting in intracellular transport to the cytosol for the MHC Class I presentation system, as well as to the endosomal pathway for the MHC Class II presentation.</abstract><subject><genre>article-category</genre><topic>Vaccines</topic></subject><subject><genre>Keywords</genre><topic>Adjuvants</topic><topic>Antigen delivery systems</topic><topic>Immune modulation</topic><topic>Cytokine</topic><topic>Cell mediated immunity</topic><topic>Antibody mediated immunity</topic></subject><relatedItem type="host"><titleInfo><title>Veterinary Immunology and Immunopathology</title></titleInfo><titleInfo type="abbreviated"><title>VETIMM</title></titleInfo><name type="conference"><namePart>Proceedings of the International Veterinary Immunology Symposium, Davis, California</namePart><namePart>IVIS</namePart><namePart type="date">199507</namePart></name><name type="personal"><namePart>Patricia E. Shewen</namePart><role><roleTerm type="text">editor</roleTerm></role></name><name type="personal"><namePart>Joan K. Lunney</namePart><role><roleTerm type="text">editor</roleTerm></role></name><name type="personal"><namePart>Laurel J. Gershwin</namePart><role><roleTerm type="text">editor</roleTerm></role></name><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1996</dateIssued></originInfo><identifier type="ISSN">0165-2427</identifier><identifier type="PII">S0165-2427(00)X0022-0</identifier><part><date>1996</date><detail type="issue"><title>Proceedings of the International Veterinary Immunology Symposium, Davis, California</title></detail><detail type="volume"><number>54</number><caption>vol.</caption></detail><detail type="issue"><number>1–4</number><caption>no.</caption></detail><extent unit="issue-pages"><start>1</start><end>389</end></extent><extent unit="pages"><start>373</start><end>384</end></extent></part></relatedItem><identifier type="istex">E36E830A8DEA0E8E1025E05505689770D30009C4</identifier><identifier type="ark">ark:/67375/6H6-D1SBLW3D-2</identifier><identifier type="DOI">10.1016/S0165-2427(96)05697-8</identifier><identifier type="PII">S0165-2427(96)05697-8</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-D1SBLW3D-2/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000655 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000655 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:E36E830A8DEA0E8E1025E05505689770D30009C4
|texte= Novel adjuvants and vaccine delivery systems
}}
| This area was generated with Dilib version V0.6.33. |  |